IASLC WCLC 2023 Conference - Fasenra, a biologic medicine, met the primary endpoint of inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe inflammatory disease.

Fasenra, a new treatment for EGPA, achieved remission in Phase III trial (IASLC WCLC 2023 Conference)

Anika Sharma

The MANDARA Phase III trial has shed new light on the effectiveness of AstraZeneca’s Fasenra (benralizumab). Unveiling favorable high-tier outcomes, ...